

Our team - experienced from research to clinic



Prof Bent Jakobsen CEO and Founder

25 years as an Immunotherapy pioneer. Scientific Founder of two unicorns: Adaptimmune Itd & Immunocore Itd



Dr Jez Gerry Head of Preclinical Development



Andy Johnson Head of CMC



Prof Hardey Pandha Head of Clinical



Prof Alan Parker Chief Scientific Officer. Trocept Therapeutics



Research

Translated >10 innovative research projects from PoC to regulatory submissions and clinical trials

Our in-depth bios can be found at: www.accessiontherapeutics.com/our-team



Translational


Dr David Krige Head of Translational science

Ranjeet Babbra Head of Quality Assurance




Nick Cross CFO and Chairman









Accession has developed a universal bispecific that targets all cancer cells to address tumor diversity...









...recruiting T cells into the tumor and potently redirecting tumor killing








Potential to kill any tumor cell regardless of antigen profile











Accession has developed a unique tumor-localizing viral platform for I.V. delivery

Solution: Accession has a unique viral delivery system that enables its universal bispecific to be only expressed in, and secreted from, tumor cells



Problem 2: This type of potent therapy must only be in the tumor






- only capable of infecting cancer cells



trocept 🕢

first-in-class I.V. delivery of tumor disrupting drugs


- overcoming the limitations of existing viral platforms



Unique

Does not target healthy cells


Trocept is a stealth virus, engineered not to infect normal cells (first time this has been done and solves main limitation of current viral therapies)



Directed

Cancer specific targeting

Trocept is 'retargeted' using an antigen specific mechanism (via ανβ6 integrin re-targeting) to home in on tumor cells




Potent


Amplifies broad tumor activity

Trocept delivers a broad and potent payload in the tumor, bypassing tumor heterogeneity and overriding tumor suppression mechanisms



Wildtype Ad5 infects normal cells







Green = virus in

liver & spleen





wildtype Ad5
infects normal cells,
mostly the liver,
reducing viral
bioavailability
for tumors






is engineered (Mods.1-3) not to infect normal cells











No Trocept in

liver or spleen

Wildtype Ad5

 infects normal cells,
 mostly the liver,
 reducing viral
 bioavailability
 for tumors










Trocept has been engineered not to target healthy cells (unique feature)

Trocept avoids elimination by the liver (chief limitation of other viral therapies)




Wildtype Ad5 infects normal cells and provides limited protection





trocept 😿

localizes to tumors (Mod.4) achieving 100% survival





trocept (\checkmark) is engineered to bind $\alpha \lor \beta 6$ integrin, a cancer specific

marker highly expressed on several indications

Carcinoma	*Incidence/year	*Deaths/year	*10 year survival %	% positive tumors
Pancreas	9,618	8,817	<]	91
Head & Neck	5,550	5,091	N/A	80-100
Stomach	6,682	4,576	15	84
Serous ovarian	2,500	1,000	15	60-100
Basal cell	60,000	450	70	75
Liver	6,214	5,635	20	70
Oesophagus	8,919	7,790	12	68
Cervical squamous	8,919	7,790	12	59
Lung	46,403	35,895	5	46
Endometrial	9,703	2,409	72	42
Breast	55,222	11,433	78	31
Kidney	12,593	4,421	50	21
Colon	41,265	15,903	57	31

*UK figures (CRUK)









Specific in tumor oncotherapy

Program: Trocept one

Stage: Pre-Clinical

Disease Area: Immuno-oncology

Indications: Epithelial origin carcinomas (inc. oesophageal, pancreatic, lung, breast, ovarian, kidney, stomach, colon, head & neck)

MoA: Viral targeting via a cancer specific marker ($\alpha \vee \beta 6$ integrin), turning infected cancer cells into drug factories, generating high doses of cancer localized immunotherapies to disrupt solid tumors

Description: Trocept one uses Accession's engineered adenovirus viral delivery platform (trocept) to generate high doses of immunotherapies directly within the tumor following systemic I.V. delivery. Trocept one only infects specific cancer cells, avoiding healthy tissue with reduced immunogenicity. Infected cancer cells then amplify a broad therapeutic response by secreting immunotherapies only in the tumor, creating highly potent in tumor activity.





trocept one: in tumor ICI delivery first in human 1H 2024


- Trocept one: in tumor delivery of immune checkpoint inhibitors
 - Addresses dose limiting toxicity and turns cold tumors hot
 - Could improve response rates in a highly attractive therapeutic area
- Rapid development into the clinic (1H 2024)
- Clinical validation of the **Trocept** virus, demonstrating safety, I.V. delivery, tumor targeting, replication and payload production





trocept one turns cancer cells into ICI drug factories

Generation of functional ICIs by trocept one infected cancer cells










High yields of ICIs generated

ICIs are fully functional in cell assays




Pipeline: parallel development of fully differentiated clinical candidates





Partnerships and collaborations



Accession is interested in early stage partnerships



Trocept could deliver partner nominated transgenes



Contact details



Prof Bent Jakobsen
CEO and Founder
Email: bent.Jakobsen@
accessiontherapeutics.com



Nick Cross
CFO and Chairman
Email: nick.cross@
accessiontherapeutics.com



OR code to JPM deck:

Research

Dr Dave Cole Head of Molecular Science Email: dave.cole@ accessiontherapeutics.com



Dr David Krige
Head of Translational science
Email: david.krige@
accessiontherapeutics.com





Dr Jez Gerry
Head of Preclinical
Development
Email: jez.gerry@
accessiontherapeutics.com



Ranjeet Babbra
Head of Quality Assurance
Email: ranjeet.babbra@
accessiontherapeutics.com



